A clinical trial to study the effect of triple combination of Triglow cream containing Hydroquinone, Tretinoin and Fluocinolone acetonide in patients with facial melasma.

Assessment of efficacy and safety of ?Triglow? Cream (Combination of Hydroquinone 2%, Tretinoin 0.05% and Fluocinolone acetonide 0.01%) in the treatment of Facial Melasma.

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2011/091/000054

Enrollment

Registered

2011-02-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Facial Melasma

Interventions

Intervention1: Triglow Cream (Combination of Hydroquinone 2%, Tretinoin 0.05% and Fluocinolone acetonide 0.01%): Triglow cream to be applied as a thin layer to the affected area on the face once daily

Eligibility

Inclusion criteria

Inclusion criteria: ? Subjects with facial Melasma and not used any topical treatments for Melasma for 2 weeks prior to enrollment in study. ? Subjects must be 18 and above. ? Subjects must provide written informed consent and comply to the protocol

Exclusion criteria

Exclusion criteria: ? Subjects who had used any topical treatment for Melasma for 2 weeks prior to enrollment in study. ? Subjects under treatment for a dermatologic condition, which may interfere with the safe evaluation of the study combination (e.g. eczema, psoriasis, severe sun-damage, dermatitis) ? Hypersensitivity to any ingredients of Triglow ? Subjects who have undergone any surgical treatment of the face. ? Subjects with a diagnosis of skin cancer in the areas to be treated.

Design outcomes

Primary

Measure	Time frame
Improvement in the Area of facialMelasma. ? Improvement in the luminance of facial MelasmaTimepoint: 4 weeks and 8 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Rajesh Lalchandani

rajeshl@glenmarkpharma.com40889082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026